Keyword: Diovan

Zhejiang Huahai Pharmaceutical informed the EMA that it had identified a chemical that might lead to cancer in its valsartan provided to the European market.

Federal prosecutors say they'll show Novartis traded fancy dinners—and in some cases, jobs for physicians' relatives—to boost prescription numbers.

The vacant Novartis manufacturing facility in Suffern, New York, sold for $18 million to a buyer who then resold it to a developer for $30 million.

A decade in biopharma has a way of featuring megablockbuster patent losses—and we mean mega, with a total $915B in lifetime sales.

Novartis has escaped a false advertising charge in Japan tied to questionable data on its heart drug Diovan. It was one of a series of missteps for the Swiss company that culminated in a 15-day suspension of its business in the country.